History - Boehringer Ingelheim Therapeutics in Ochsenhausen, Germany
PEI Approval for IVD, Virus Manufacturing, Biosafety Testing, Vaccine Release Testing, GMP Certificate, GLP Certificate, GMP production Plant, FDA Inspection, Foundation, PEI Approval for IVD, Virus Manufacturing, Biosafety Testing, Vaccine Release Testing, GMP Certificate, CLP Certificate, GMP Produktion Plant, FDA Inspection
1143
page-template,page-template-full_width,page-template-full_width-php,page,page-id-1143,page-child,parent-pageid-415,ajax_fade,page_not_loaded,,qode-title-hidden,qode_grid_1300,footer_responsive_adv,qode-child-theme-ver-1.0.0,qode-theme-ver-13.6,qode-theme-bridge,disabled_footer_top,wpb-js-composer js-comp-ver-6.6.0,vc_responsive

History

History

Founded in 1971, Boehringer Ingelheim Therapeutics formerly known as Labor Dr. Merk & Kollegen is based in Ochsenhausen, Germany and was a family owned company, performing R&D and clinical manufacturing with a focus on ATMP (Advanced Therapy Medicinal Products)-based cancer immunology treatments.before being acquired by Boehringer Ingelheim in 2021.

1971

Foundation

1975

PEI Approval for IVD

1993

Virus Manufacturing

1998

Biosafety Testing

2004

Vaccine Release Testing

2008

GMP Certificate

2013

GLP Certificate

2018

GMP Production Plant

2018

FDA Inspection

2021

Acquisition by Boehringer Ingelheim

Labor Dr. Merk & Kollegen operates under the new company name Boehringer Ingelheim Therapeutics.